伤口世界

伤口世界

电子邮件地址: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

“表皮屏障受损及分层修复”新理念

何黎

[摘 要] 广义的皮肤屏障包括物理屏障、神经屏障、色素屏障及免疫屏障。 狭义的皮肤屏障通常指表皮屏障。 既往研究主要集中在角质层,忽视了表皮其他层次的屏障修复。 近年研究表明,多种皮肤疾病及皮肤问题的表皮屏障受损不仅在角质层,还涉及颗粒层、棘层及基底层,且角化包膜、细胞间脂质及紧密连接蛋白变化也是表皮屏障受损的关键因素。 但迄今为止,仍缺乏对表皮屏障不同层次受损机制及干预的系统探讨。 本文提出“表皮屏障受损及分层修复”新理念,为表皮屏障受损不同层次的精准修复提供理论依据及临床应用新视角。

[关键词] 皮肤屏障;表皮屏障;屏障修复;紧密连接蛋白

[中图分类号] R 751 [文献标志码] A [文章编号] 1001 - 7089(2025)09 - 0945 - 08[DOI] 10. 13735 / j. cjdv. 1001⁃7089. 202502028

The New Concept of “Epidermal Barrier Damage and Stratified Repair”HE Li1,2

(1. Department of Dermatology,First Affiliated Hospital of Kunming Medical University, Kunming650032,China; 2. Liwa Institute of Skin Health, East China Normal University,Shanghai 200062,China)

[Abstract] The skin barrier in a broad sense includes the physical barrier, neural barrier,pigment barrier, and immune barrier, while the skin barrier in a narrow sense generally refers to the epidermal barrier. Previous studies have mainly focused on thestratum corneum, neglecting barrier repair in other epidermal layers. Recent studies have revealed that epidermal barrier damage in various dermatoses and skin conditions involves not only the stratum corneum but also the stratum granulosum, stratum spinosum, and stratum basale, with alterations in the cornified envelope, intercellular lipids, and tight junction proteins being key contributing factors. However, systematic investigations into the damage mechanisms and targeted interventions for different epidermal barrier layers remain lacking. This article proposes the new concept of “ epidermal barrier damage and stratified repair ”, providing both a theoretical framework and new clinical insights for layer⁃specific precision repair of the epidermal barrier.

[Key words] Skin barrier;Epidermal barrier;Barrier repair;Tight junction proteins

光声电治疗术后皮肤黏膜屏障修复专家共识

中华医学会医学美容学会激光美容学组,中华医学会皮肤性病学会美容激光学组

 

[关键词] 皮肤黏膜修复,光声电治疗术后;共识

[中图分类号] R751.05 [文献标识码] B [文章编号] 1000-4963(2019)05-0319-04

doi:10.16761/j.cnki.1000-4963.2019.05.019

妊娠期高血糖诊治指南(2022)[第二部分]

中华医学会妇产科学分会产科学组

中华医学会围产医学分会

中国妇幼保健协会妊娠合并糖尿病专业委员会

通信作者:杨慧霞,北京大学第一医院妇产科,北京 100034,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【摘要】 妊娠期高血糖包括妊娠期不同类型的糖代谢异常,与巨大胎儿、剖宫产术分娩、早产、子痫前期等不良妊娠结局明确相关,且远期母儿代谢综合征的发生风险增高。伴随我国生育政策的不断调整,妊娠期高血糖的发生率升高,妊娠期规范化管理能明确降低上述不良妊娠结局的发生。本指南旨在进一步改善妊娠期高血糖的母儿结局。指南第一部分已发表于《中华妇产科杂志》2022年第57卷第1期,内容包括妊娠期高血糖的分类、诊断、孕前保健、营养管理、运动管理、药物治疗。本文为指南第二部分,内容包括孕妇糖脂代谢等指标的监测、母儿并发症、围产期处理、产后管理与随防、妊娠期糖尿病的预防。

基金项目:国家重点研发计划(2016YFC1000402,2016YFC1000303)

DOI:10.3760/cma.j.cn112141-20210917-00529

收稿日期 2021-09-17    本文编辑 张楠

引用本文:中华医学会妇产科学分会产科学组, 中华医学会围产医学分会, 中国妇幼保健协会妊娠合并糖尿病专业委员会 . 妊娠期高血糖诊治指南(2022)[第二部分][J]. 中华妇产科杂志, 2022, 57(2): 81-90.

DOI: 10.3760/cma.j.cn112141-20210917-00529.

妊娠期高血糖诊治指南(2022)[第一部分]

中华医学会妇产科学分会产科学组 中华医学会围产医学分会

中国妇幼保健协会妊娠合并糖尿病专业委员会

通信作者:杨慧霞,北京大学第一医院妇产科,北京 100034,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【摘要】 妊娠期高血糖包括妊娠期不同类型的糖代谢异常,与巨大胎儿、剖宫产术分娩、早产、子痫前期等不良妊娠结局明确相关,且远期母儿代谢综合征的发生风险增高。伴随我国生育政策的不断调整,妊娠期高血糖的发生率升高,妊娠期规范化管理能明确降低上述不良妊娠结局的发生。本指南将对妊娠期高血糖的分类以及不同类型糖代谢异常的孕前、孕期及产后的监测和管理进行阐述,旨在进一步改善妊娠期高血糖的母儿结局。

基金项目: 国家重点研发计划(2016YFC1000402,2016YFC1000303)

DOI:10.3760/cma.j.cn112141-20210917-00528

收稿日期 2021-09-17

本文编辑 张楠

引用本文:中华医学会妇产科学分会产科学组, 中华医学会围产医学分会, 中国妇幼保健协会妊娠合并糖尿病专业委员会 . 妊娠期高血糖诊治指南(2022)[第一部分][J]. 中华妇产科杂志, 2022, 57(1): 3-12.DOI: 10.3760/cma.j.cn112141-20210917-00528.

中国玫瑰痤疮诊疗指南(2021版)

中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会

通信作者:李吉,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。;谢红付,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【摘要】 玫瑰痤疮是一种好发于面中部的慢性炎症性皮肤病,主要表现为面中部反复潮红、红斑。近年来,对本病的诊治有了新的认识,为此,组织部分专家在《中国玫瑰痤疮诊疗专家共识(2016)》的基础上制定本指南,新版指南提出了分部位诊断标准,希望能进一步规范我国玫瑰痤疮的诊断与治疗。

【关键词】 红斑痤疮;指南;诊断;治疗

DOI:10.35541/cjd.20201078

Guidelines for the diagnosis and treatment of rosacea in China(2021 edition)

Rosacea Research Center, Chinese Society of Dermatology; Rosacea Professional Committee, ChineseDermatologist AssociationCorresponding authors: Li Ji, Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。; Xie Hongfu, Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【Abstract】 Rosacea, a chronic inflammatory skin disease primarily affecting central areas of the face, mainly manifests as recurrent flushing and erythema on the central face. In recent years, there has been progress in the understanding of its diagnosis and treatment. To this end, some experts were organized to establish this guideline on the basis of“diagnosis and treatment of rosacea in China: an expert consensus statement(2016)”. The new guideline proposes diagnostic criteria for rosacea at different sites, aiming to further standardize the diagnosis and treatment of rosacea in China.

【Key words】 Rosacea; Guideline; Diagnosis; Treatment

DOI: 10.35541/cjd.20201078

糖尿病患者合并心血管疾病诊治专家共识

国家卫生健康委员会能力建设和继续教育中心 孙艺红1 陈康2 陈歆3 谷伟军2 郭远林4 李一君2 刘彤5 彭道泉6 母义明2 马长生5

1 中日友好医院心脏科,北京 100029;2 解放军总医院第一医学中心内分泌科,北京 100853;3 上海交通大学医学院附属瑞金医院高血压科 200025;4 中国医学科学院 北京 协和医学院 阜外医院心血管内科,北京100037;5 首都医科大学附属北京安贞医院心脏 内科中心 国家心血管疾病临床医学研究中心 100029;6 中南大学湘雅二医院心血管内 科,长沙 410011

通信作者:母义明,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。;马长生,Email:chshma@vip. sina.com

【提要】 糖尿病是心血管疾病最重要的合并疾病,心血管疾病是 2型糖尿病患者致死致残的主要原因。为规范糖尿病合并心血管疾病患者的诊疗,国家卫生健康委员会能力建设和继续教育中心组织心脏科和内分泌科领域的专家,总结国内外相关学科研究进展及专家经验,制定了本共识。本共识分别从心血管疾病和糖尿病管理的角度进行阐述,涵盖糖尿病合并心血管疾病(主要包括动脉粥样硬化性心血管病和心力衰竭)的诊断、药物治疗及危险因素管理等相关的临床重要内容,旨在加强患者的综合管理并最终改善患者预后。心血管疾病的管理主要包括血压、血脂、抗栓、抗心肌缺血、抗心室重构等。糖尿病的管理主要包括生活方式干预、降糖、血糖监测治疗及低血糖预防。此外,本共识还针对特殊人群如糖尿病肾病、高龄(>75岁)及心血管危重症等患者给出了具体的临床建议。

【关键词】 糖尿病; 冠心病; 心力衰竭; 血压; 血脂; 降糖治疗、

Expert consensus on the management of diabetic patients with cardiovascular diseases

National Health Commissim Capacity Buiding and Continuing Education Center, Sun Yihong1 ,Chen Kang2 , Chen Xin3 , Gu Weijun2 , Guo Yuanlin4 , Li Yijun2 , Liu Tong5 , Peng Daoquan6 , Mu Yiming2 ,Ma Changsheng

1Department of Cardiology, China‑Japan Friendship Hospital, Beijing 100029, China; 2 Department ofEndocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China;3Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai 200025, China; 4 Department of Cardiology, Fuwai Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100037, China; 5 Department of Cardiology, BeijingAnzhen Hospital, Capital Medical University, National Center for Cardiovascular Diseases, Beijing100029, China; 6Department of Cardiology, the Second Xiangya Hospital of Central South University,Changsha 410011, China

[Summary]Diabetes is the most important comorbidity of cardiovascular disease, andcardiovascular disease is the main cause of mortality and disability of patients with type 2 diabetes.In order to standardize the diagnosis and treatment of patients with diabetes and cardiovasculardisease, the National Health Commission Capacity Building and Continuing Education Centerorganized the experts from the field of cardiology and endocrinology systematically reviewing theresearch progresses and expert experiences of relevant disciplines from home and abroad, and formulated this consensus. This consensus covers the diagnosis, drug treatment, and risk factor management for patients with diabetes and cardiovascular disease (including atherosclerotic cardiovascular disease and heart failure) from the perspective of cardiovascular disease and diabetes management aiming to strengthen the comprehensive management of patients and ultimately to improve the prognosis of patients. The management of cardiovascular diseases mainly includes the management of blood pressure, blood lipids, anti‑thrombosis, anti‑myocardial ischemia, anti‑ventricular remodeling and so on. Diabetes management mainly includes lifestyle intervention (including diet, exercise, weight loss, etc.), anti‑hyperglycemia therapy (including drugs and insulin), blood glucose monitoring, and hypoglycemic prevention. In addition, specific clinical recommendations are given to patients with special health care needs such as diabetic nephropathy, elderly (>75 years), and cardiovascular critical illness.

Key words】 Diabetes mellitus; Coronary heart disease; Heart failure; Blood pressure; Blood lipid; Anti‑hyperglycemic treatment